Skip to content
SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials episode artwork

EPISODE · Jan 15, 2026 · 14 MIN

SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials

from BiotechTV - News · host BiotechTV

Plus, how the neuroscience company has used its long history working with corticotropin releasing factor to move into obesity, with a project that acts on targets in the brain.

Episode metadata supplied by the publisher feed · Published Jan 15, 2026

Embed this episode

Ready to play

SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials

0:00 14:24

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 14 minutes long.

When was this BiotechTV - News episode published?

This episode was published on January 15, 2026.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!